Aladdin Healthcare Technologies SE, a leading developer of A.I healthcare diagnostics and drug discovery applications for age-related diseases, has signed a memorandum of understanding (MOU) with the OurHealthMate India (OHM) to validate and subsequently distribute its COVID-19 diagnosis prototype through their industry network.

OHM is recognised by clinicians of the Indian Medical Council and have access to their databases, ensuring that they only work with and provide appointments with accredited healthcare providers.

It is India's largest healthcare marketplace with 40,000 doctors on their system and more than 350,000 medical services available. They are integrated with over 2,000 healthcare centers in India, including the majority of the large hospital chains in India.

The platform is believed to have access to millions of patients and currently hosts more than 1,500,000 medical records on its platform.Access to quality data is vital for accuracy of any COVID-19 diagnosis tool. This is the problem facing any company that is attempting to develop a rapid and accurate product. As a result of this partnership, Aladdin will have access to Indian data as part of a global resource of high-quality data, putting the company at a significant advantage to competitors.

The capability of the prototype, once validated, will be expanded so that it can recognise and diagnose other pulmonary diseases in real time. Meaning the commercial longevity of the product will reach far beyond the COVID-19.

"We intend to push this product out to millions of patients within India over the next 2 years post validation for both COVID-19 and other pulmonary diseases diagnosis. This should culminate in Aladdin becoming an early leader in A.I. imaging services for complex medical conditions in India," said Wade Menpes-Smith, CEO von Aladdin Healthcare Technologies SE.

A public offering of shares in the company is open and runs from 9 to 30 March 2020.

Aladdin Healthcare Technologies has signed an MoU with OurHealthMate India (OHM) to validate and distribute its COVID-19 diagnosis prototype through their industry network.